Market Place
Sourcing Support
Humacyte Presents V007 Ph 3 AV Trial Results at VEITH Symposium
22 Nov 2024 //
GLOBENEWSWIRE
Humacyte’s ATEV™ Benefits in Arterial Injury Repair Published
21 Nov 2024 //
GLOBENEWSWIRE
Humacyte Prices $15M Registered Direct Offering
14 Nov 2024 //
GLOBENEWSWIRE
Humacyte Q3 2024 Financial Results & Business Update
08 Nov 2024 //
GLOBENEWSWIRE
Humacyte to Present Q3 Financial Results & Corporate Update
06 Nov 2024 //
GLOBENEWSWIRE
Humacyte Presents Positive V007 Phase 3 Results at ASN Kidney Week
28 Oct 2024 //
GLOBENEWSWIRE
Humacyte Hosts KOL Event on Acellular Tissue Engineered Vessel
23 Oct 2024 //
GLOBENEWSWIRE
Humacyte issues raised in 483 appear ‘fixable,’ says BTIG
18 Oct 2024 //
TIPRANKS
Humacyte Abstract Accepted For ASN Kidney Week 2024 Presentation
08 Oct 2024 //
GLOBENEWSWIRE
Humacyte Announces Pricing Of $30.0 Million Offering
04 Oct 2024 //
GLOBENEWSWIRE
Humacyte To Host Virtual KOL Event On Vascular Trauma Treatment
26 Sep 2024 //
GLOBENEWSWIRE
Humacyte Announces Patent Allowance For BioVascular Pancreas
19 Sep 2024 //
GLOBENEWSWIRE
Humacyte to Participate at Upcoming Investor Conferences in September
03 Sep 2024 //
GLOBENEWSWIRE
Humacyte Presents ATEV Results In Vascular Trauma From Ukraine Program
27 Aug 2024 //
GLOBENEWSWIRE
Humacyte Second Quarter 2024 Financial Results and Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Humacyte To Present Q2 Results And Corporate Update On August 13
12 Aug 2024 //
GLOBENEWSWIRE
Humacyte Announces FDA Needs More Time To Review ATEV™ BLA
09 Aug 2024 //
GLOBENEWSWIRE
Humacyte ATEV™ Meets Primary Endpoints In Phase 3 Trial
31 Jul 2024 //
GLOBENEWSWIRE
Humacyte Adds Bamforth And Jones To Board Of Directors
16 Jul 2024 //
GLOBENEWSWIRE
Humacyte ATEV Receives FDA`s RMAT Designation For PAD
01 Jul 2024 //
GLOBENEWSWIRE
Humacyte Presents Positive Preclinical Data for BioVascular Pancreas Program
25 Jun 2024 //
GLOBENEWSWIRE
CMS Issues ICD-10-PCS Codes For Humacyte’s Human Acellular Vessel™ (HAV™)
17 Jun 2024 //
GLOBENEWSWIRE
Humacyte to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Humacyte to Participate at Upcoming Investor Conferences in May
13 May 2024 //
GLOBENEWSWIRE
Humacyte First Quarter 2024 Financial Results and Business Update
10 May 2024 //
GLOBENEWSWIRE
Humacyte To Present Q1 Results, Corporate Update On May 10
06 May 2024 //
GLOBENEWSWIRE
Humacyte to Host Virtual KOL Event Hemodialysis Access: A Crossroads of Care
26 Mar 2024 //
GLOBENEWSWIRE
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22 Mar 2024 //
GLOBENEWSWIRE
Humacyte to Present 2023 Fourth Quarter & Year-End Financial Results & Provide
18 Mar 2024 //
GLOBENEWSWIRE
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
01 Mar 2024 //
GLOBENEWSWIRE
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
29 Feb 2024 //
GLOBENEWSWIRE
Humacyte Announces Pricing of $40.2 Million Public Offering of Common Stock
29 Feb 2024 //
GLOBENEWSWIRE
HAV BLA Granted Priority Review by U.S. FDA for Vascular Trauma
09 Feb 2024 //
GLOBENEWSWIRE
Humacyte Submits BLA to U.S. FDA Seeking Approval of Human Acellular Vessel
12 Dec 2023 //
GLOBENEWSWIRE
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Results
17 Nov 2023 //
GLOBENEWSWIRE
Humacyte Third Quarter 2023 Financial Results and Business Update
09 Nov 2023 //
GLOBENEWSWIRE
Humacyte to Present Third Quarter Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel Patency
16 Oct 2023 //
GLOBENEWSWIRE
Humacyte to Present at the Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20
18 Sep 2023 //
GLOBENEWSWIRE
Humacyte Announces Positive Results from Phase 2/3 of Human Acellular Vessel
12 Sep 2023 //
GLOBENEWSWIRE
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma
11 Sep 2023 //
GLOBENEWSWIRE
Humacyte Presents Clinical Performance of Human Acellular Vessel
15 Aug 2023 //
GLOBENEWSWIRE
Humacyte Second Quarter 2023 Financial Results and Business Update
14 Aug 2023 //
GLOBENEWSWIRE
Humacyte to Present Second Quarter Financial Results on August 14, 2023
07 Aug 2023 //
GLOBENEWSWIRE
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel
26 Jul 2023 //
GLOBENEWSWIRE
Humacyte to Present at the Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Humacyte and Oberland Announce Funding Arrangement Totaling Up to $160 Million
12 May 2023 //
GLOBENEWSWIRE
Humacyte First Quarter 2023 Financial Results and Business Update
12 May 2023 //
GLOBENEWSWIRE
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting
09 May 2023 //
GLOBENEWSWIRE
Humacyte to Present First Quarter Financial Results and Provide Corporate Update
05 May 2023 //
GLOBENEWSWIRE
Humacyte’s Human Acellular Vessel™ Receives FDA’s RMAT
04 May 2023 //
GLOBENEWSWIRE
Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas
27 Apr 2023 //
GLOBENEWSWIRE
Humacyte Announces Publication of Preclinical Study Comparing Human Acellular
18 Apr 2023 //
GLOBENEWSWIRE
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel
11 Apr 2023 //
GLOBENEWSWIRE
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Humacyte to Present Fourth Quarter and Full Year Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
